New insights into the pathogenesis of systemic sclerosis.

[1]  Yunliang Chen,et al.  Dysregulation of transforming growth factor beta signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts. , 2002 .

[2]  A. Gabrielli,et al.  Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. , 2002, Arthritis and rheumatism.

[3]  R. Abbate,et al.  High prevalence of polymorphisms of angiotensin-converting enzyme (I/D) and endothelial nitric oxide synthase (Glu298Asp) in patients with systemic sclerosis. , 2002, The American journal of medicine.

[4]  M. Hillarby,et al.  Increased gelatinase activity in systemic sclerosis dermal fibroblast cultures with unaltered gelatinase A mRNA expression. , 2002, Journal of dermatological science.

[5]  D. Abraham,et al.  Connective tissue growth factor: A new and important player in the pathogenesis of fibrosis , 2002, Current rheumatology reports.

[6]  S. Jimenez,et al.  Oligoclonal T Cell Expansion in the Skin of Patients with Systemic Sclerosis1 , 2002, The Journal of Immunology.

[7]  P. Goldschmidt-Clermont,et al.  Deficient Smad7 expression: A putative molecular defect in scleroderma , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[8]  S. Bombardieri,et al.  Systemic Sclerosis: Demographic, Clinical, and Serologic Features and Survival in 1,012 Italian Patients , 2002, Medicine.

[9]  R. Silver,et al.  Thrombin Differentiates Normal Lung Fibroblasts to a Myofibroblast Phenotype via the Proteolytically Activated Receptor-1 and a Protein Kinase C-dependent Pathway* , 2001, The Journal of Biological Chemistry.

[10]  M. Landthaler,et al.  Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. , 2001, Arthritis and rheumatism.

[11]  J. Gailit,et al.  The differentiation and function of myofibroblasts is regulated by mast cell mediators. , 2001, The Journal of investigative dermatology.

[12]  S. Sa,et al.  The control of ccn2 (ctgf) gene expression in normal and scleroderma fibroblasts , 2001, Molecular pathology : MP.

[13]  M. Mayes,et al.  Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. , 2001, Arthritis and rheumatism.

[14]  D. Milewicz,et al.  Association of fibrillin 1 single-nucleotide polymorphism haplotypes with systemic sclerosis in Choctaw and Japanese populations. , 2001, Arthritis and rheumatism.

[15]  N. Sepp,et al.  Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. , 2000, Arthritis and rheumatism.

[16]  Y. Akiyama,et al.  Clinical, serological and genetic study in patients with CREST syndrome. , 2000, Internal medicine.

[17]  P. Clements.  Systemic sclerosis (scleroderma) and related disorders: clinical aspects. , 2000, Bailliere's best practice & research. Clinical rheumatology.

[18]  F. Arnett,et al.  Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin 1, in patients with localized scleroderma. , 1999, Arthritis and rheumatism.

[19]  Y. Muro,et al.  Anti-annexin V antibodies and digital ischemia in patients with scleroderma. , 1999, The Journal of rheumatology.

[20]  C. Querfeld,et al.  Expression of TGF-β1, -β2 and -β3 in localized and systemic scleroderma , 1999 .

[21]  B. Giraudeau,et al.  Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis? , 1999, Chest.

[22]  R. D. du Bois,et al.  Different cytokine profiles in cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a quantitative study of open lung biopsies. , 1999, The European respiratory journal.

[23]  R. Wise,et al.  Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. , 1999, Arthritis and rheumatism.

[24]  R. Rezzonico,et al.  Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T cells: different sensitivity to inhibition between systemic sclerosis and control fibroblasts. , 1998, Arthritis and rheumatism.

[25]  K. Nishioka,et al.  Expression of Stem Cell Factor in the Lesional Skin of Systemic Sclerosis , 1998, Dermatology.

[26]  S. Jimenez,et al.  Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. , 1998, The New England journal of medicine.

[27]  Kurosawa,et al.  Dermal mast cells in scleroderma: their skin density, tryptase/chymase phenotypes and degranulation , 1998, The British journal of dermatology.

[28]  V. Negi,et al.  Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. , 1998, The Journal of rheumatology.

[29]  D. Furst,et al.  Microchimerism and HLA-compatible relationships of pregnancy in scleroderma , 1998, The Lancet.

[30]  S. Jimenez,et al.  A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation. , 1996, Genome research.

[31]  S. Bombardieri,et al.  Anti‐collagen antibodies in systemic sclerosis and in primary Raynaud's phenomenon , 1995, Clinical and experimental immunology.

[32]  T. Medsger,et al.  Autoantibody Reactive with RNA Polymerase III in Systemic Sclerosis , 1993, Annals of Internal Medicine.

[33]  M. Trucco,et al.  Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations. , 1992, Arthritis and rheumatism.

[34]  T. Medsger,et al.  Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. , 1988, Arthritis and rheumatism.

[35]  T. Medsger,et al.  HLA and clinical associations in systemic sclerosis patients with anti-Th/To antibodies. , 1998, Arthritis and rheumatism.

[36]  C. Bona,et al.  Spontaneous occurrence of anti-fibrillin-1 autoantibodies in tight-skin mice. , 1998, Autoimmunity.

[37]  C. Savage,et al.  IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. , 1996, The Journal of clinical investigation.

[38]  R. Bashey,et al.  Regulation of connective tissue synthesis in systemic sclerosis. , 1995, International reviews of immunology.

[39]  T. Medsger,et al.  Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. , 1992, Arthritis and rheumatism.